Vadodara, January 30, 2025 – Rekvina Laboratories Limited has reported its unaudited financial results for the quarter and nine months ended December 31, 2024.
Financial Highlights (₹ in Lakhs)
| Particulars | Q3 FY2025 | Q2 FY2025 | Q3 FY2024 | 9M FY2025 | 9M FY2024 | FY2024 (Audited) |
|---|---|---|---|---|---|---|
| Revenue from Operations | - | - | - | - | - | - |
| Other Income | - | - | - | - | - | - |
| Total Income | - | - | - | - | - | - |
| Total Expenses | 2.43 | 6.65 | 0.43 | 9.42 | 1.43 | 1.64 |
| Net Profit/(Loss) | (2.43) | (6.65) | (0.43) | (9.42) | (1.43) | (1.64) |
| EPS (₹) | (0.040) | (0.110) | (0.007) | (0.156) | (0.024) | (0.027) |
- The company reported no revenue or income during the quarter.
- Expenses stood at ₹2.43 lakh for Q3 FY2025, down from ₹6.65 lakh in Q2 FY2025.
- Net loss for Q3 FY2025 was ₹2.43 lakh, worsening from ₹0.43 lakh in Q3 FY2024.
- Cumulative net loss for the nine months ended December 31, 2024, stands at ₹9.42 lakh.
Business Segment & Corporate Disclosures
- The company operates in a single business segment (Trading of Goods), making segmental reporting inapplicable.
- No financial indebtedness reported, with zero outstanding loans or debt securities.
- No exceptional items recorded during the reporting period.
- No related party transactions disclosed in the half-yearly filing.
- The company does not have lease contracts, making certain accounting standards non-applicable.
Audit Review and Compliance
- The independent auditors conducted a limited review as per regulatory requirements.
- The review did not reveal any material misstatements in the financials.
Outlook & Future Considerations
- The company’s continued lack of revenue raises concerns about sustainability.
- Cost controls and expense reduction strategies have led to a decline in quarterly losses.
- Investors will seek management's strategy on revenue generation and business operations in upcoming quarters.